Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib plus nivolumab plus /- ipilimumab

被引：0
|
作者：
Iannantuono, Giovanni Maria
Chandran, Elias
Simon, Nicholas I.
Ley, Lisa
Cordes, Lisa M.
Wang, Tzu-fang
Girardi, Daniel da Motta
Gurram, Sandeep
Valera, Vladimir
Chalfin, Heather
Parnes, Howard L.
Nadal, Rosa
Niglio, Scot Anthony
Boudjadi, Salah
Banday, Abdul Rouf
Kydd, Andre Rashad
Steinberg, Seth M.
Apolo, Andrea B.
机构：
[1] NCI, Genitourinary Malignancies Branch, CCR, NIH, Bethesda, MD USA
[2] Hosp Sirio Libanes, Brasilia, MD, Brazil
[3] NCI, Urol Oncol Branch, CCR, NIH, Bethesda, MD USA
[4] Frederick Hlth Hosp, Frederick, MD USA
[5] NCI, Div Canc Prevent, CCR, NIH, Bethesda, MD USA
[6] NHLBI, Cellular & Mol Therapeut Branch, Lab Transplantat Immunotherapy, NIH, Bethesda, MD USA
[7] NYU, Grossman Sch Med, New York, NY USA
[8] NCI, Biostat & Data Management Sect, OCD, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [2] Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
    Zhou, Shi
    Khanal, Samrat
    Zhang, Haijun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 211 - 221
  • [3] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [4] Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab
    Remolina-Bonilla, Yuly A.
    Jimenez-Franco, Brenda
    Lam, Elaine T.
    Bourlon, Maria T.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 171 - 174
  • [5] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Muto, Yumina
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2022, 207 (05): : E175 - E175
  • [6] Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib plus nivolumab (CaboNivo) or cabozantinib plus nivolumab plus ipilimumab (CaboNivoIpi).
    Niglio, Scot Anthony
    Girardi, Daniel Motta
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [8] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Toshiyuki Sumi
    Motoki Sekikawa
    Yuta Nagahisa
    Keigo Matsuura
    Naoki Shijubou
    Koki Kamada
    Hiroki Watanabe
    Yuichi Yamada
    Yusuke Tanaka
    Hirofumi Chiba
    Investigational New Drugs, 2022, 40 : 1315 - 1321
  • [9] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Sumi, Toshiyuki
    Sekikawa, Motoki
    Nagahisa, Yuta
    Matsuura, Keigo
    Shijubou, Naoki
    Kamada, Koki
    Watanabe, Hiroki
    Yamada, Yuichi
    Tanaka, Yusuke
    Chiba, Hirofumi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1315 - 1321
  • [10] Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)
    Lin, Jeffrey
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Francis, Deneise C.
    Berniger, Marilise Anne
    Monk, Paul
    Kempf, Jeffrey
    Becker, Murray
    Sokol, Levi
    McKinney, Yolanda
    Knopp, Michael V.
    Wright, Chadwick
    Jung, Alex
    Choyke, Peter L.
    Mena, Esther
    Lindenberg, Liza
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345